Physiomics inks strategic deal with Medicines Discovery Catapult

The AIM-traded firm said it would be part of the MDC's ‘Virtual R&D’ network of advisors, and available to provide advice to small biotechnology companies supported by the MDC from its Alderley Park base.

Under the terms of the agreement, the MDC would introduce Physiomics to “selected potential clients”, and in return would receive a small commission on the value of any service contracts arising from such introductions.

“We are delighted to be working with the MDC - an organisation that plays such a key role in supporting emerging biotech companies in the UK,” said Physiomics chief executive officer Jim Millen.

“We're also excited by the potential that this new relationship offers to connect Physiomics to emerging players in the field of oncology,” Dr Millen added.